Agency Information Collection Activities: Submission for OMB Review; Comment Request, 40077-40079 [2019-17282]
Download as PDF
<![CDATA[
40077
Federal Register / Vol. 84, No. 156 / Tuesday, August 13, 2019 / Notices
ESTIMATED ANNUAL REPORTING REQUIREMENT BURDEN FOR OPIOID TREATMENT PROGRAMS—Continued
Purpose
8.11(e)(1) ............
8.11(e)(2) ............
Application for provisional certification
Application for extension of provisional certification.
Notification of sponsor or medical director change (SMA–162).
Documentation to SAMHSA for interim maintenance.
Request to SAMHSA for Exemption
from 8.11 and 8.12 (including
SMA–168).
Notification to SAMHSA Before Establishing Medication Units (SMA–162).
Notification to State Health Officer
When Patient Begins Interim Maintenance.
Contents of Appellant Request for Review of Suspension.
Informal Review Request ....................
Appellant’s Review File and Written
Statement.
Appellant’s Request for Expedited Review.
Appellant Review File and Written
Statement.
8.11(f)(5) .............
8.11(g)(2) ............
8.11(h) ................
8.11(i)(1) .............
8.12(j)(2) .............
8.24 .....................
8.25(a) ................
8.26(a) ................
8.28(a) ................
8.28(c) ................
Responses/
respondent
Total
responses
Hours/
response
Total
hours
42
30
1
1
42
30
1
0.25
42.00
7.50
60
1
60
0.1
6.00
1
1
1
1
1.00
1,200
20
24,000
0.07
1,680
10
1
10
0.25
2.5
1
20
20
0.33
6.6
2
1
2
0.25
.50
2
2
1
1
2
2
1.00
5.00
2.00
10.00
2
1
2
1.00
2.00
2
1
2
5.00
10.00
Subtotal .......
.............................................................
1,775
........................
24,594
........................
1,868.95
Total .....
.............................................................
1,829
........................
26,001
........................
2,263.15
Written comments and
recommendations concerning the
proposed information collection should
be sent by September 12, 2019 to the
SAMHSA Desk Officer at the Office of
Information and Regulatory Affairs,
Office of Management and Budget
(OMB). To ensure timely receipt of
comments, and to avoid potential delays
in OMB’s receipt and processing of mail
sent through the U.S. Postal Service,
commenters are encouraged to submit
their comments to OMB via email to:
OIRA_Submission@omb.eop.gov.
Although commenters are encouraged to
send their comments via email,
commenters may also fax their
comments to: 202–395–7285.
Commenters may also mail them to:
Office of Management and Budget,
Office of Information and Regulatory
Affairs, New Executive Office Building,
Room 10102, Washington, DC 20503.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
establish policy, direct program
activities, and better allocate resources.
Substance Abuse and Mental Health
Services Administration
2020 NSDUH Main Study
Summer King,
Statistician.
The National Survey on Drug Use and
Health (NSDUH) is a survey of the U.S.
civilian, non-institutionalized
population aged 12 years old or older.
The data are used to determine the
prevalence of use of tobacco products,
alcohol, illicit substances, and illicit use
of prescription drugs. The results are
used by SAMHSA, the Office of
National Drug Control Policy (ONDCP),
federal government agencies, and other
organizations and researchers to
[FR Doc. 2019–17261 Filed 8–12–19; 8:45 am]
BILLING CODE 4162–20–P
jspears on DSK3GMQ082PROD with NOTICES
Number of
respondents
42 CFR citation
VerDate Sep<11>2014
17:51 Aug 12, 2019
Jkt 247001
Agency Information Collection
Activities: Submission for OMB
Review; Comment Request
Periodically, the Substance Abuse and
Mental Health Services Administration
(SAMHSA) will publish a summary of
information collection requests under
OMB review, in compliance with the
Paperwork Reduction Act (44 U.S.C.
Chapter 35). To request a copy of these
documents, call the SAMHSA Reports
Clearance Officer on (240) 276–1112.
Project: 2020 National Survey on Drug
Use and Health, Clinical Validation
Study and Redesign Field Test (OMB
No. 0930–0110)—Revision to 2019
NSDUH Collection
PO 00000
Frm 00058
Fmt 4703
Sfmt 4703
NSDUH must be updated periodically
to reflect changing substance use and
mental health issues and to continue
producing current data. For the 2020
NSDUH main study the following
changes from 2019 are planned: (1) The
addition of lifetime and recency
questions about vaping anything and
vaping nicotine or tobacco; the addition
of lifetime and recency questions on
synthetic marijuana and synthetic
stimulants; (2) the addition of questions
in concordance with the Diagnostic and
Statistical Manual of Mental Disorders
(DSM), fifth edition criteria (DSM–5) to
measure the occurrence of marijuana
withdrawal symptoms, occurrence of
prescription tranquilizer misuse
withdrawal symptoms and occurrence
of craving for all substances; (3) minor
revisions to the marijuana marketplace
module; and (4) other minor wording
changes to improve the flow of the
interview, increase respondent
comprehension or to be consistent with
text in other questions.
By including these new questions in
NSDUH, estimates may be generated on
the use of these substances among the
general population and allow SAMHSA
to provide national-level estimates
among adults and adolescents on the
E:\FR\FM\13AUN1.SGM
13AUN1
40078
Federal Register / Vol. 84, No. 156 / Tuesday, August 13, 2019 / Notices
use of vaping, synthetic marijuana, and
synthetic stimulants. In addition,
because NSDUH collects demographic,
socioeconomic, and health information
about each respondent, the inclusion of
these questions would permit a more
detailed understanding of factors
associated with their use.
The new questions on craving for all
substances and withdrawal for
marijuana/cannabis were added to the
2020 NSDUH main study to reflect the
updated DSM–5 diagnostic criteria for
substance use disorders. Questions
measuring withdrawal for tranquilizers
have been added to ensure SUD for
tranquilizers is accurately assessed as
well.
The marijuana marketplace module
(originally dropped in the 2015 redesign
questionnaire) was reinserted in the
NSDUH main study questionnaire
starting in 2018 at the request of ONDCP
but was unchanged from the version
previously used in the 2014 NSDUH.
(This module was not part of the
NSDUH questionnaire from 2015–2017.)
This module consists of a series of
questions that seek to gather data such
as the location, quantity, cost and type
of marijuana being purchased across the
nation. Revisions have been made to
this module for 2020 to reflect the
availability that marijuana can now be
purchased from a retail store or
dispensary.
As with all NSDUH/NHSDA surveys
conducted since 1999, the sample size
of the NSDUH main study for 2020 will
be sufficient to permit prevalence
estimates for each of the fifty states and
the District of Columbia. (Prior to 2002,
the NSDUH was referred to as the
National Household Survey on Drug
Abuse (NHSDA). The total annual
burden estimate for the NSDUH main
study is shown below in Table 1.
TABLE 1—ANNUALIZED ESTIMATED BURDEN FOR 2020 NSDUH
Number of
respondents
Instrument
Responses
per
respondent
Total
number of
responses
Hours per
response
Total
burden
hours
Household Screening ...........................................................
Interview ...............................................................................
Screening Verification ..........................................................
Interview Verification ............................................................
143,255
69,007
4,348
10,351
1
1
1
1
143,255
69,007
4,348
10,351
0.083
1.000
0.067
0.067
11,890
69,007
291
694
Total ..............................................................................
143,255
........................
226,961
........................
81,882
Clinical Validation Study
In addition, a Clinical Validation
Study (CVS) is planned to be embedded
within the first six months of 2020
NSDUH main study data collection to
assess revisions to the substance use
disorders (SUD) module to be consistent
with the DSM–5. The CVS will examine
the validity of this revised NSDUH
assessment of SUD by administering
questions to adults and adolescents who
will then be interviewed by clinical
interviewers (who are blinded to the
NSDUH main study responses) and
classified as having or not having
substance use disorders based on past
year DSM–5 disorders, as assessed by
the Structured Clinical Interview for
DSM–5 (SCID–5)
During CVS data collection from
January through June 2020,
approximately 1,500 NSDUH main
study interview respondents will be
selected for a follow-up clinical
interview at the end of the main study
interview in order to produce a final
sample size of approximately 826 CVS
respondents. These follow-up clinical
interviews will be conducted via
telephone using the SCID–5 within two
to four weeks following the NSDUH
main study interview.
Many of the procedures and protocols
planned for inclusion in this CVS are
based upon those previously employed
as part of the 2018 National Mental
Health Study (approved under OMB No.
0930–0380) and the 2008–2012 NSDUH
Mental Health Surveillance Study
(approved as an add-on to NSDUH
under OMB No. 0930–0110).
Also, to complete training prior to
CVS data collection, each clinical
interviewer candidate hired must
successfully administer the follow-up
clinical interview with a volunteer
respondent. These 70 certification
interviews will be administered in the
same manner as CVS follow-up clinical
interviews.
The total annual burden estimate for
the CVS is shown below in Table 2.
TABLE 2—ANNUALIZED ESTIMATED BURDEN FOR 2020 NSDUH CVS
Number of
respondents
Instrument
Total
number of
responses
Hours per
response
Total
burden
hours
Follow-Up Clinical Interviews ...............................................
Follow-Up Clinical Certifications ..........................................
800
70
1
1
800
70
0.83
0.83
664
58
Total ..............................................................................
870
........................
870
........................
722
Redesign Field Test
jspears on DSK3GMQ082PROD with NOTICES
Responses
per
respondent
Also, as part of SAMHSA’s ongoing
effort to ensure NSDUH continues
producing current and accurate data, a
Redesign Field Test (FT) is planned
from August through November 2020 to
assess potential revisions to the NSDUH
main study questionnaire. These
VerDate Sep<11>2014
17:51 Aug 12, 2019
Jkt 247001
revisions are designed to address
changing policy and research data
needs; in addition, modifications to
associated survey materials and
methods are designed to improve the
quality of estimates and the efficiency of
data collection. Planned FT
modifications include changes to
respondent incentives, respondent
PO 00000
Frm 00059
Fmt 4703
Sfmt 4703
materials, the household screening
questionnaire, the interview
questionnaire, and other data collection
methods.
The FT is essential for providing a
thorough examination of these planned
changes prior to their deployment on
the NSDUH main study to determine
potential impact across operational and
E:\FR\FM\13AUN1.SGM
13AUN1
40079
Federal Register / Vol. 84, No. 156 / Tuesday, August 13, 2019 / Notices
substantive domains, including effects
on data quality (as measured by
outcomes such as unit nonresponse,
item nonresponse, and survey
responses), questionnaire timing, data
collection efficiency, and possible
differences in reporting of substance use
or mental health items.
During FT data collection from
August through November 2020,
conducted separately from ongoing 2020
NSDUH main study data collection at
that time, screenings will be completed
with approximately 8,110 Englishspeaking respondents in the contiguous
United States. (Alaska and Hawaii are
excluded from the FT to control study
costs.) From those screenings,
approximately 4,000 respondents, as
representatives of the civilian,
noninstitutional population aged 12
years old or older, are expected to
complete a FT interview using the
revised questionnaire and materials.
For the NSDUH FT screening,
revisions may include: (1) A revised
roster structure; (2) various wording
edits to improve respondent
comprehension and flow; (3) the use of
revised materials, such as the lead letter,
study description and question &
answer brochure; (4) a conditional test
of a $5 screening incentive to assess
impact on response rates; and (5) the
inclusion of two outcome questions on
past month alcohol and past month
cigarette use at the end of the screening
to assess nonresponse bias from the
screening incentive.
For the NSDUH FT interview,
revisions may include: (1) A conditional
test of a $50 interview incentive to
assess impact on response rates; (2)
revisions to the DSM–5-based SUD
module as a result of prior testing in the
CVS; (3) the inclusion of new modules
on substance use treatment and mental
health service utilization; (4) the
addition of new and/or revised
questions on a variety of items such as
Electronic Nicotine Delivery Systems
(ENDS), synthetic drugs, pain and sleep,
vaping and needle use, and criminal
justice; (5) the addition of measures of
adolescent psychological distress and/or
impairment; (6) the expansion of suicide
items; and (7) other general
questionnaire revisions such as
clarifying wording and terminology,
reordering for improved question flow,
formatting changes, removal of
questions with low prevalence rates,
and other minor updates and revisions.
The total annual burden estimate for
the FT is shown below in Table 3.
TABLE 3—ANNUALIZED ESTIMATED BURDEN FOR REDESIGN FIELD TEST
Number of
respondents
Instrument
Total
number of
responses
Hours per
response
Total
burden
hours
Household Screening ...........................................................
Interview ...............................................................................
Screening Verification ..........................................................
Interview Verification ............................................................
8,110
4,000
246
600
1
1
1
1
8,110
4,000
246
600
0.083
1.000
0.067
0.067
673
4,000
17
40
Total ..............................................................................
8,110
........................
12,596
........................
4,730
Written comments and
recommendations concerning the
proposed information collection should
be sent by September 12, 2019 to the
SAMHSA Desk Officer at the Office of
Information and Regulatory Affairs,
Office of Management and Budget
(OMB). To ensure timely receipt of
comments, and to avoid potential delays
in OMB’s receipt and processing of mail
sent through the U.S. Postal Service,
commenters are encouraged to submit
their comments to OMB via email to:
OIRA_Submission@omb.eop.gov.
Although commenters are encouraged to
send their comments via email,
commenters may also fax their
comments to: 202–395–7285.
Commenters may also mail them to:
Office of Management and Budget,
Office of Information and Regulatory
Affairs, New Executive Office Building,
Room 10102, Washington, DC 20503.
jspears on DSK3GMQ082PROD with NOTICES
Responses
per
respondent
Summer King,
Statistician.
[FR Doc. 2019–17282 Filed 8–12–19; 8:45 am]
BILLING CODE 4162–20–P
VerDate Sep<11>2014
17:51 Aug 12, 2019
Jkt 247001
DEPARTMENT OF HOMELAND
SECURITY
U.S. Customs and Border Protection
Test Concerning Entry of Section 321
Low-Valued Shipments Through
Automated Commercial Environment
(ACE)
U.S. Customs and Border
Protection, Department of Homeland
Security.
ACTION: General notice.
AGENCY:
SUMMARY: This document announces
that U.S. Customs and Border Protection
(CBP) is conducting a test of new
functionalities related to the electronic
entry filing for low-valued shipments
through the Automated Commercial
Environment (ACE). The Section 321 de
minimis administrative exemption
admits free from duty and tax,
shipments of merchandise (other than
bona-fide gifts and certain personal and
household goods) imported by one
person on one day having an aggregate
fair retail value in the country of
shipment of not more than $800. During
this test, an owner, or purchaser of a
Section 321 low-valued shipment or,
when appropriately designated, a
customs broker appointed by an owner,
PO 00000
Frm 00060
Fmt 4703
Sfmt 4703
purchaser, or consignee, will be able to
file a new type of informal entry in ACE
for Section 321 low-valued shipments.
Section 321 low-valued shipments
subject to Partner Government Agency
(PGA) requirements will also be able to
be entered using this new Section 321
informal entry type. This notice
provides a description of the test, the
requirements for filing the new informal
entry type, and the regulations that will
be waived for test participants. CBP
invites public comment concerning the
test program. The test will be known as
the ACE Entry Type 86 Test.
DATES: The test will commence no
earlier than September 28, 2019 and
will continue until concluded by an
announcement published in the Federal
Register. Comments will be accepted
throughout the duration of the test.
ADDRESSES: Comments concerning this
notice and any aspect of this test may
be submitted at any time during the test
via email to OTENTRYSUMMARY@
cbp.dhs.gov. In the subject line of your
email, please indicate, ‘‘Comment on
the ACE Entry Type 86 Test.’’
FOR FURTHER INFORMATION CONTACT:
Randy Mitchell, Director, Commercial
Operations, Revenue and Entry
Division, Office of Trade, U.S. Customs
E:\FR\FM\13AUN1.SGM
13AUN1
]]>Agencies
[Federal Register Volume 84, Number 156 (Tuesday, August 13, 2019)]
[Notices]
[Pages 40077-40079]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-17282]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Substance Abuse and Mental Health Services Administration
Agency Information Collection Activities: Submission for OMB
Review; Comment Request
Periodically, the Substance Abuse and Mental Health Services
Administration (SAMHSA) will publish a summary of information
collection requests under OMB review, in compliance with the Paperwork
Reduction Act (44 U.S.C. Chapter 35). To request a copy of these
documents, call the SAMHSA Reports Clearance Officer on (240) 276-1112.
Project: 2020 National Survey on Drug Use and Health, Clinical
Validation Study and Redesign Field Test (OMB No. 0930-0110)--Revision
to 2019 NSDUH Collection
The National Survey on Drug Use and Health (NSDUH) is a survey of
the U.S. civilian, non-institutionalized population aged 12 years old
or older. The data are used to determine the prevalence of use of
tobacco products, alcohol, illicit substances, and illicit use of
prescription drugs. The results are used by SAMHSA, the Office of
National Drug Control Policy (ONDCP), federal government agencies, and
other organizations and researchers to establish policy, direct program
activities, and better allocate resources.
2020 NSDUH Main Study
NSDUH must be updated periodically to reflect changing substance
use and mental health issues and to continue producing current data.
For the 2020 NSDUH main study the following changes from 2019 are
planned: (1) The addition of lifetime and recency questions about
vaping anything and vaping nicotine or tobacco; the addition of
lifetime and recency questions on synthetic marijuana and synthetic
stimulants; (2) the addition of questions in concordance with the
Diagnostic and Statistical Manual of Mental Disorders (DSM), fifth
edition criteria (DSM-5) to measure the occurrence of marijuana
withdrawal symptoms, occurrence of prescription tranquilizer misuse
withdrawal symptoms and occurrence of craving for all substances; (3)
minor revisions to the marijuana marketplace module; and (4) other
minor wording changes to improve the flow of the interview, increase
respondent comprehension or to be consistent with text in other
questions.
By including these new questions in NSDUH, estimates may be
generated on the use of these substances among the general population
and allow SAMHSA to provide national-level estimates among adults and
adolescents on the
[[Page 40078]]
use of vaping, synthetic marijuana, and synthetic stimulants. In
addition, because NSDUH collects demographic, socioeconomic, and health
information about each respondent, the inclusion of these questions
would permit a more detailed understanding of factors associated with
their use.
The new questions on craving for all substances and withdrawal for
marijuana/cannabis were added to the 2020 NSDUH main study to reflect
the updated DSM-5 diagnostic criteria for substance use disorders.
Questions measuring withdrawal for tranquilizers have been added to
ensure SUD for tranquilizers is accurately assessed as well.
The marijuana marketplace module (originally dropped in the 2015
redesign questionnaire) was reinserted in the NSDUH main study
questionnaire starting in 2018 at the request of ONDCP but was
unchanged from the version previously used in the 2014 NSDUH. (This
module was not part of the NSDUH questionnaire from 2015-2017.) This
module consists of a series of questions that seek to gather data such
as the location, quantity, cost and type of marijuana being purchased
across the nation. Revisions have been made to this module for 2020 to
reflect the availability that marijuana can now be purchased from a
retail store or dispensary.
As with all NSDUH/NHSDA surveys conducted since 1999, the sample
size of the NSDUH main study for 2020 will be sufficient to permit
prevalence estimates for each of the fifty states and the District of
Columbia. (Prior to 2002, the NSDUH was referred to as the National
Household Survey on Drug Abuse (NHSDA). The total annual burden
estimate for the NSDUH main study is shown below in Table 1.
Table 1--Annualized Estimated Burden for 2020 NSDUH
----------------------------------------------------------------------------------------------------------------
Number of Responses per Total number Hours per Total burden
Instrument respondents respondent of responses response hours
----------------------------------------------------------------------------------------------------------------
Household Screening............. 143,255 1 143,255 0.083 11,890
Interview....................... 69,007 1 69,007 1.000 69,007
Screening Verification.......... 4,348 1 4,348 0.067 291
Interview Verification.......... 10,351 1 10,351 0.067 694
-------------------------------------------------------------------------------
Total....................... 143,255 .............. 226,961 .............. 81,882
----------------------------------------------------------------------------------------------------------------
Clinical Validation Study
In addition, a Clinical Validation Study (CVS) is planned to be
embedded within the first six months of 2020 NSDUH main study data
collection to assess revisions to the substance use disorders (SUD)
module to be consistent with the DSM-5. The CVS will examine the
validity of this revised NSDUH assessment of SUD by administering
questions to adults and adolescents who will then be interviewed by
clinical interviewers (who are blinded to the NSDUH main study
responses) and classified as having or not having substance use
disorders based on past year DSM-5 disorders, as assessed by the
Structured Clinical Interview for DSM-5 (SCID-5)
During CVS data collection from January through June 2020,
approximately 1,500 NSDUH main study interview respondents will be
selected for a follow-up clinical interview at the end of the main
study interview in order to produce a final sample size of
approximately 826 CVS respondents. These follow-up clinical interviews
will be conducted via telephone using the SCID-5 within two to four
weeks following the NSDUH main study interview.
Many of the procedures and protocols planned for inclusion in this
CVS are based upon those previously employed as part of the 2018
National Mental Health Study (approved under OMB No. 0930-0380) and the
2008-2012 NSDUH Mental Health Surveillance Study (approved as an add-on
to NSDUH under OMB No. 0930-0110).
Also, to complete training prior to CVS data collection, each
clinical interviewer candidate hired must successfully administer the
follow-up clinical interview with a volunteer respondent. These 70
certification interviews will be administered in the same manner as CVS
follow-up clinical interviews.
The total annual burden estimate for the CVS is shown below in
Table 2.
Table 2--Annualized Estimated Burden for 2020 NSDUH CVS
----------------------------------------------------------------------------------------------------------------
Number of Responses per Total number Hours per Total burden
Instrument respondents respondent of responses response hours
----------------------------------------------------------------------------------------------------------------
Follow-Up Clinical Interviews... 800 1 800 0.83 664
Follow-Up Clinical 70 1 70 0.83 58
Certifications.................
-------------------------------------------------------------------------------
Total....................... 870 .............. 870 .............. 722
----------------------------------------------------------------------------------------------------------------
Redesign Field Test
Also, as part of SAMHSA's ongoing effort to ensure NSDUH continues
producing current and accurate data, a Redesign Field Test (FT) is
planned from August through November 2020 to assess potential revisions
to the NSDUH main study questionnaire. These revisions are designed to
address changing policy and research data needs; in addition,
modifications to associated survey materials and methods are designed
to improve the quality of estimates and the efficiency of data
collection. Planned FT modifications include changes to respondent
incentives, respondent materials, the household screening
questionnaire, the interview questionnaire, and other data collection
methods.
The FT is essential for providing a thorough examination of these
planned changes prior to their deployment on the NSDUH main study to
determine potential impact across operational and
[[Page 40079]]
substantive domains, including effects on data quality (as measured by
outcomes such as unit nonresponse, item nonresponse, and survey
responses), questionnaire timing, data collection efficiency, and
possible differences in reporting of substance use or mental health
items.
During FT data collection from August through November 2020,
conducted separately from ongoing 2020 NSDUH main study data collection
at that time, screenings will be completed with approximately 8,110
English-speaking respondents in the contiguous United States. (Alaska
and Hawaii are excluded from the FT to control study costs.) From those
screenings, approximately 4,000 respondents, as representatives of the
civilian, noninstitutional population aged 12 years old or older, are
expected to complete a FT interview using the revised questionnaire and
materials.
For the NSDUH FT screening, revisions may include: (1) A revised
roster structure; (2) various wording edits to improve respondent
comprehension and flow; (3) the use of revised materials, such as the
lead letter, study description and question & answer brochure; (4) a
conditional test of a $5 screening incentive to assess impact on
response rates; and (5) the inclusion of two outcome questions on past
month alcohol and past month cigarette use at the end of the screening
to assess nonresponse bias from the screening incentive.
For the NSDUH FT interview, revisions may include: (1) A
conditional test of a $50 interview incentive to assess impact on
response rates; (2) revisions to the DSM-5-based SUD module as a result
of prior testing in the CVS; (3) the inclusion of new modules on
substance use treatment and mental health service utilization; (4) the
addition of new and/or revised questions on a variety of items such as
Electronic Nicotine Delivery Systems (ENDS), synthetic drugs, pain and
sleep, vaping and needle use, and criminal justice; (5) the addition of
measures of adolescent psychological distress and/or impairment; (6)
the expansion of suicide items; and (7) other general questionnaire
revisions such as clarifying wording and terminology, reordering for
improved question flow, formatting changes, removal of questions with
low prevalence rates, and other minor updates and revisions.
The total annual burden estimate for the FT is shown below in Table
3.
Table 3--Annualized Estimated Burden for Redesign Field Test
----------------------------------------------------------------------------------------------------------------
Number of Responses per Total number Hours per Total burden
Instrument respondents respondent of responses response hours
----------------------------------------------------------------------------------------------------------------
Household Screening............. 8,110 1 8,110 0.083 673
Interview....................... 4,000 1 4,000 1.000 4,000
Screening Verification.......... 246 1 246 0.067 17
Interview Verification.......... 600 1 600 0.067 40
-------------------------------------------------------------------------------
Total....................... 8,110 .............. 12,596 .............. 4,730
----------------------------------------------------------------------------------------------------------------
Written comments and recommendations concerning the proposed
information collection should be sent by September 12, 2019 to the
SAMHSA Desk Officer at the Office of Information and Regulatory
Affairs, Office of Management and Budget (OMB). To ensure timely
receipt of comments, and to avoid potential delays in OMB's receipt and
processing of mail sent through the U.S. Postal Service, commenters are
encouraged to submit their comments to OMB via email to:
[email protected]. Although commenters are encouraged to send
their comments via email, commenters may also fax their comments to:
202-395-7285. Commenters may also mail them to: Office of Management
and Budget, Office of Information and Regulatory Affairs, New Executive
Office Building, Room 10102, Washington, DC 20503.
Summer King,
Statistician.
[FR Doc. 2019-17282 Filed 8-12-19; 8:45 am]
BILLING CODE 4162-20-P
